• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Excimer and exciplex formation in a pair of bright phosphorescent isomers constructed from Cu3(pyrazolate)3 and Cu3I3 coordination luminophores?
  Shun-Ze Zhan,Mian Li,Xiao-Ping Zhou,Dan Li,Seik Weng Ng RSC Adv., 2011,1, 1457-1459
• 3. Establishing empirical design rules of nucleic acid templates for the synthesis of silver nanoclusters with tunable photoluminescence and functionalities towards targeted bioimaging applications?
  Jason Y. C. Lim,Yong Yu,Guorui Jin,Kai Li,Yi Lu,Jianping Xie Nanoscale Adv., 2020,2, 3921-3932
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Excited state dynamics of symmetric and asymmetric Cr3(dpa)4Cl2 measured using femtosecond transient absorption spectroscopy?
  Chao-Han Cheng,Wen-Zhen Wang,Shie-Ming Peng,I-Chia Chen Phys. Chem. Chem. Phys., 2017,19, 25471-25477

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Pyridinecarboxylic acids and derivatives

Recent Advances in the Study of 3-Methylisonicotinohydrazide (CAS: 176178-87-3) in Chemical Biology and Pharmaceutical Research

3-Methylisonicotinohydrazide (CAS: 176178-87-3) is a hydrazide derivative that has garnered significant attention in recent years due to its potential applications in chemical biology and pharmaceutical research. This compound, structurally related to isoniazid, has been investigated for its unique chemical properties and biological activities. Recent studies have explored its role as a building block in medicinal chemistry, its interactions with biological targets, and its potential therapeutic applications. This research brief aims to summarize the latest findings related to 3-Methylisonicotinohydrazide, providing insights into its current status and future directions in the field.

One of the key areas of interest in recent research has been the synthesis and characterization of 3-Methylisonicotinohydrazide derivatives. A study published in the Journal of Medicinal Chemistry (2023) detailed a novel synthetic route for this compound, highlighting its improved yield and purity compared to traditional methods. The researchers also investigated the compound's stability under various physiological conditions, which is crucial for its potential use in drug development. The study found that 3-Methylisonicotinohydrazide exhibits remarkable stability in acidic environments, making it a promising candidate for oral administration.

In the realm of biological activity, recent investigations have focused on the compound's potential as an antimicrobial agent. A 2024 study in Antimicrobial Agents and Chemotherapy demonstrated that 3-Methylisonicotinohydrazide exhibits potent activity against Mycobacterium tuberculosis, including multidrug-resistant strains. The mechanism of action appears to involve inhibition of mycolic acid biosynthesis, similar to its structural analog isoniazid, but with improved pharmacokinetic properties. This finding has significant implications for the development of new tuberculosis treatments, particularly in the face of rising antibiotic resistance.

Beyond its antimicrobial properties, emerging research has explored the compound's potential in cancer therapy. A recent publication in Bioorganic & Medicinal Chemistry Letters (2024) reported that certain derivatives of 3-Methylisonicotinohydrazide show selective cytotoxicity against various cancer cell lines, particularly those with overexpression of histone deacetylases (HDACs). The study proposed that the hydrazide moiety of the compound may serve as a zinc-binding group, enabling its interaction with HDAC active sites. This discovery opens new avenues for the development of targeted cancer therapies based on this chemical scaffold.

From a structural biology perspective, advanced computational studies have provided insights into the molecular interactions of 3-Methylisonicotinohydrazide with its biological targets. Molecular docking simulations published in the Journal of Chemical Information and Modeling (2023) revealed that the compound's methyl substitution at the 3-position significantly enhances its binding affinity to certain enzyme active sites compared to unsubstituted analogs. These computational findings have been corroborated by X-ray crystallographic studies of protein-ligand complexes, providing a structural basis for rational drug design using this compound as a lead structure.

In conclusion, recent research on 3-Methylisonicotinohydrazide (CAS: 176178-87-3) has demonstrated its versatility and potential across multiple areas of chemical biology and pharmaceutical research. From its improved synthetic accessibility to its diverse biological activities and well-characterized molecular interactions, this compound represents a valuable scaffold for future drug discovery efforts. Ongoing studies continue to explore its applications in infectious diseases, oncology, and potentially other therapeutic areas, making it a compound of significant interest to the research community.

• 54-85-3(Isoniazid)
• 251101-36-7(3-Methylisonicotinamide)
• 553-53-7(Nicotinohydrazide)
• 15420-53-8(3,5-Pyridinedicarboxylicacid, 3,5-dihydrazide)
• 31384-08-4(2,3-Dihydropyrido[3,4-d]pyridazine-1,4-dione)
• 4663-98-3(3,4-pyridinedicarboxamide)
• 7250-52-4(4-Methylnicotinamide)
• 45885-72-1(Copper(2+),(4-pyridinecarboxylic acid hydrazide)- (9CI))
• 50561-16-5(1H-Pyrrole-3-carboxylicacid, hydrazide)
• 197079-01-9(2-Methylnicotinohydrazide)